Spending on prescription drugs to grow to $5.7 trillion by 2026

That would be faster than other health care services

A pharmacist holds prescription painkiller OxyContin made by Purdue Pharma LP at a local pharmacy in Provo, Utah, U.S., April 25, 2017.   REUTERS/George Frey
A pharmacist holds prescription painkiller OxyContin made by Purdue Pharma LP at a local pharmacy in Provo, Utah, U.S., April 25, 2017. REUTERS/George Frey

Prescription drug spending will grow faster than any other major medical good or service over the next decade, according to a projection from the Centers for Medicare and Medicaid Services.

The analysis, published in the journal Health Affairs, estimates that by 2026, national health spending will climb to $5.7 trillion, or nearly a fifth of the economy.

Prescription drug spending is forecast to grow at 6.3 percent per year, on average, between 2017 to 2026.

Drug spending skyrocketed in 2014 and 2015, driven largely by the use of a new generation of curative therapies for hepatitis C.

When national health spending data was released in December showing a mere 1.3 percent increase in spending on prescription drugs in 2016 — a fraction of the increases in previous years — a pharmaceutical lobby spokeswoman highlighted the trend as evidence of the “nation’s competitive marketplace for medicines.”

The new analysis suggests that the low rate of increase won’t last. CMS actuaries said the secret rebates that manufacturers negotiate with health plans have helped temper the growth of prescription drug prices and spending in recent years but won’t contribute as much going forward.

The prescription drug data does not include drugs administered in physicians’ offices or hospitals.


The rebates have become a major part of the pharmaceutical industry’s recent lobbying efforts, with a push for patients to receive the secretly negotiated rebates directly, when they fill their prescriptions.

Critics of the industry have argued that although such a measure could provide some relief to some people, it will further insulate drug prices from any downward pressure.

The new data suggests that while rebates have been successful at helping to rein in prescription drug spending, the effect will attenuate over the next decade. The spending growth also will be driven by a shift toward specialty drugs, which cost more and often don’t carry as generous rebates.

“We’re not anticipating that drug rebates will be smaller, just anticipating that as a share of drug costs, it won’t be growing as fast as it has in past years,” said Sean Keehan, an economist in the CMS Office of the Actuary.



CHICAGO/MEXICO CITY - Mexican buyers imported ten times more corn from Brazil last year amid concern that NAFTA renegotiations could disrupt their U.S. supplies, according to government data and top grains merchants.Mexico is on t ...

WASHINGTON - U.S. President Donald Trump on Thursday pushed his call to arm teachers following last week's school massacre in Florida, saying it would be limited to those with military or special training but 'would solve the prob ...

Give us feedback

Have you found an error or omission in our reporting? Tell us here.

Do you have a story idea we should look into? Tell us here.